BG
VYGR icon

BlackRock Group’s Voyager Therapeutics VYGR Stock Holding History

BlackRock Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$183K Hold
14,401
– – ﹤0.01% 2683
2016
Q3 		$173K Hold
14,401
– – ﹤0.01% 2676
2016
Q2 		$158K Buy
+14,401
New +$176K ﹤0.01% 2656

Other funds holding VYGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock Group's VYGR Position: Q4 2016 in Review

BlackRock Group held its Voyager Therapeutics (VYGR) position steady in Q4 2016 at 14,401 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

BlackRock Group first reported a position in VYGR in Q2 2016 and has held it in 3 quarters since. 56 funds tracked by Wall St. Rank hold VYGR as of Q4 2016.

  • BlackRock Group held 14,401 shares of Voyager Therapeutics worth $183K as of Q4 2016.
  • BlackRock Group left its Voyager Therapeutics share count unchanged in Q4 2016.
  • Voyager Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2683 holding.
  • BlackRock Group first reported a position in Voyager Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • 56 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.